JANXJanux Therapeutics, Inc.

$852M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$29M

Net Income

-$20M

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$39M

Stockholders' Equity

$1.0B

Cash & Equivalents

$431M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	$2M	-100.0%
Operating Income	-$29M	-$16M	-79.8%
Net Income	-$20M	-$12M	-71.9%

JANX Q4 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena